Despite the challenges inherent in biosimilars, they have a fairly high probability of success, said Edric Engert, managing director of Abraxeolus Consulting, in a presentation at the 14th Biosimilars Summit, held January 22-23, 2019, in Alexandria, Virginia.
Despite the challenges inherent in biosimilars, they have a fairly high probability of success, said Edric Engert, managing director of Abraxeolus Consulting, in a presentation at the 14th Biosimilars Summit, held January 22-23, 2019, in Alexandria, Virginia.
According to Engert, people continue to see biosimilars as a particularly risky endeavor largely because of the difficulty of developing these products, challenges related to pricing and uptake, the number of potential competitors, and innovator defenses, among other factors.
Despite challenges, said Engert, it is possible to manage risks in order to capture rewards. He provided a hypothetical example of a biosimilar developer that was able to develop a product (for which the reference product has $4 billion in sales) in 7 years and launch it in 10 years.
Assuming 4 biosimilar competitors, and 80% eventual biosimilar penetration, a developer could start with a 35% discount to the reference product and continue to drop that price by 8% each year while also investing $13 million in marketing and hiring a sales force of representatives, and they company will have a net present value of $480 million for the product. Even assuming the hypothetical product’s launch was delayed by as much as 4 years, he said, the net present value would still be $265 million.
Some basic steps can bring discipline to risk identification to reap those rewards, said Engert. First, developers should pick their highest priorities to focus on first: “You can’t do everything at once.” Once the key issues have been identified, “it’s all about identifying the downstream implications.”
For challenges like intellectual property issues, for example, a developer might need to forge an internal legal team, join a trade association, or engage in contingency planning. If commercialization issues are the concern, the company might choose to engage with HHS, deepen its policy and government affairs understanding, and seek to truly understand the complexity of its portfolio choices.
Next, it’s important for developers to understand how operations will be affected, then enter into detailed planning and refine those plans through honestly assessing internal challenges. “We’re so focused on the risks that we’re facing as an industry…it’s very easy sometimes to neglect the things we’re facing within ourselves.”
For example, in assessing a portfolio, it’s useful to remember that, currently, oncology is number 1 in terms of the number of projects in the innovator pipeline; thus, oncology is also where future losses of patent exclusivity will occur. Developers need to make a strategic decision on how big a role oncology will play in their portfolios, and that involves understanding the buy-and-bill landscape for oncology centers and investigating all available settings for oncology products.
In considering marketing their drugs, biosimilar developers will have to plan to engage in activities that resemble a branded launch. They will need to consider their core message development, engage healthcare provider advisory boards, and engage in public relations, among other activities. Market access undertakings will involve assessing CMS reimbursement, creating a net pricing model, and contracting with group purchasing organizations. Distribution will require early planning and refinement of approach.
Through early planning in these areas, concluded Engert, developers can achieve substantial rewards from biosimilars. “Yes there are lots of risks. And we should be talking about the risks,” he said. “But don’t lose sight of the ball here. There is a significant return.”
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.